Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples